Company Description
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington’s disease (HD).
The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD.
Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
| Country | Singapore |
| Founded | 2012 |
| IPO Date | Nov 11, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 268 |
| CEO | Paul B. Bolno |
Contact Details
Address: Marina One East Tower, 7 Straits View No.12-00 Singapore, 018936 Singapore | |
| Phone | 65 6236 3388 |
| Website | wavelifesciences.com |
Stock Details
| Ticker Symbol | WVE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001631574 |
| CUSIP Number | Y95308105 |
| ISIN Number | SG9999014716 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul B. Bolno M.B.A., M.D. | President, Chief Executive Officer and Director |
| Kyle B. Moran CFA | Chief Financial Officer and Principal Accounting Officer |
| Dr. Chandra Vargeese Ph.D. | Chief Technology Officer |
| Dr. Erik Ingelsson M.D., Ph.D. | Chief Scientific Officer |
| Kate Rausch | Head of Investor Relations |
| Linda Rockett J.D. | Senior Vice President and General Counsel |
| Dr. Christopher Francis Ph.D. | Senior Vice President of Corporate Development and Head of Emerging Areas |
| Daryn Lewis | Senior Vice President and Head of Human Resources |
| Dr. Sridhar Vaddeboina Ph.D. | Senior Vice President of Chemistry, Manufacturing and Controls |
| Anne-Marie Li-Kwai-Cheung | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 144 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 8, 2024 | 144 | Filing |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |